Leerink analyst David Risinger raised the firm’s price target on Bristol Myers (BMY) to $60 from $54 and keeps an Outperform ...
Leerink Partners analyst David Risinger maintained a Buy rating on AbbVie yesterday. The company’s shares closed yesterday at $220.75.
Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.
Detailed price information for Bristol-Myers Squibb Company (BMY-N) from The Globe and Mail including charting and trades.
Detailed price information for Halozyme Therapeutic (HALO-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback